Fibrocell (FCSC) Reports Third Quarter 2016 Financial Results And Recent Operational Highlights
11/3/2016 7:53:01 AM
EXTON, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the third quarter ended September 30, 2016 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.
“Fibrocell is focused on advancing our innovative gene therapy candidates that use genetically-modified autologous fibroblast cells to target the underlying cause of debilitating skin and connective tissue diseases and have the potential to offer hope and relief to patients,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell. “We are pleased with the progress of the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), and continue to expect to dose the first subject in the Phase I portion of the trial at the end of 2016. Furthermore, development of FCX-013—our product candidate for the treatment of linear scleroderma—will be proceeding into a pre-clinical dose-ranging study this month, with a toxicology/biodistribution study to follow.”
comments powered by